BioStem files registration statement with SEC, to pursue Nasdaq listing
BioStem Technologies announced the filing of a Form 10 registration statement with the SEC to register its shares of common stock pursuant to the Securities Exchange Act of 1934, as amended, and reaffirmed its strategic decision to pursue a listing on Nasdaq. "The filing of our Registration Statement is an important milestone that advances our path toward a Nasdaq uplisting and reflects our significant commitment to operating as an SEC reporting company," said Jason Matuszewski, CEO and chairman of BioStem Technologies. "We believe this is the right step for the Company as we continue to strengthen our position in the public markets. Completing the registration process will be a pivotal step toward a Nasdaq uplisting and will enhance our credibility, expand access to capital, improve market visibility and liquidity, and reinforce our ability to attract exceptional talent as we continue to grow. Together, we believe these advantages will better position BioStem to execute our long-term growth strategy and create sustainable value for shareholders."
BioStem Technologies announced the filing of a Form 10 registration statement with the SEC to register its shares of common stock pursuant to the Securities Exchange Act of 1934, as amended, and reaffirmed its strategic decision to pursue a listing on Nasdaq. "The filing of our Registration Statement is an important milestone that advances our path toward a Nasdaq uplisting and reflects our significant commitment to operating as an SEC reporting company," said Jason Matuszewski, CEO and chairman of BioStem Technologies. "We believe this is the right step for the Company as we continue to strengthen our position in the public markets.
Completing the registration process will be a pivotal step toward a Nasdaq uplisting and will enhance our credibility, expand access to capital, improve market visibility and liquidity, and reinforce our ability to attract exceptional talent as we continue to grow.
Together, we believe these advantages will better position BioStem to execute our long-term growth strategy and create sustainable value for shareholders."